Conditions

This post was originally published on this site Adding the investigational oral therapy onvansertib to a regimen of Zytiga (abiraterone acetate) and prednisone overcomes resistance to Zytiga in men with metastatic castration-resistant prostate cancer (mCRPC), according to early results of a Phase 2 clinical trial. The study (NCT03414034) is testing whether a once-daily dose of…

This post was originally published on this site Inherited mutations in the DNA repair gene BRCA2 — a well-known risk factor for breast and ovarian cancers in adults — also show a significant association with non-Hodgkin’s lymphoma in children and adolescents, a new study found. Survivors of childhood lymphoma, particularly those with a family history of…

This post was originally published on this site The nonprofit organization Genome Canada, the pharmaceutical company Thermo Fisher Scientific and the Ontario Institute for Cancer Research (OICR) are collaborating to develop new targeted next generation sequencing (NGS) methods to assess, and possibly improve, the management of pancreatic, prostate, and breast cancer. The three-year, $6 million…

This post was originally published on this site The longer women use hormone therapy after menopause the higher is their breast cancer risk over time, and this risk persists for more than a decade after stopping this replacement therapy, a new meta-analysis suggests. “Type and timing of menopausal hormone therapy and breast cancer risk: individual…

This post was originally published on this site Immune checkpoint inhibitors targeting the PD-L1 molecule appear to activate immune cells called natural killer (NK) cells, a new study says. This finding may explain why some tumors are responsive to these checkpoint inhibitors even when the PD-L1 checkpoint protein isn’t expressed. The new study, “The mechanism…

This post was originally published on this site A combination of Gazyva (obinutuzumab) and Revlimid (lenalidomide) is effective for some patients with follicular lymphoma who failed prior treatments, including those with early relapses, according to a Phase 2 study in which more than 70% of the patients responded to induction therapy. With a manageable safety…

This post was originally published on this site Shlomit Norman was 42 when doctors diagnosed her with multiple myeloma — an incurable bone marrow cancer that rarely strikes people under the age of 65. At the time, the youngest of her three boys was 10, and few patients with the disease survived for more than…

This post was originally published on this site A combination of Hemispherx Biopharma‘s investigational treatment Ampligen (rintatolimod) with chemo-immunotherapy is safe and effective in treating women with recurrent ovarian cancer, according to the final report of a Phase 1 study. While chemotherapy and immunotherapies have shown promise in fighting ovarian cancers, their activity may be…

This post was originally published on this site The addition of Keytruda (pembrolizumab) to standard therapy — Revlimid (lenalidomide) or Pomalyst (pomalidomide) in combination with dexamethasone — failed to improve the clinical outcomes of patients with untreated or relapsed/refractory multiple myeloma, data from two Phase 3 trials show. Findings from the trials were published in…

This post was originally published on this site A new assay that grows patients’ cancer tissue in the lab and tests for treatment sensitivity may be able to spot ovarian cancer patients likely to respond best to first-line chemotherapy, a study showed. The ex vivo 3D cell culture (EV3D) assay, developed by Kiyatec, may lead…